article Open AccessTop 1% cited

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

New England Journal of Medicine · 2011 · Vol. 365(10) · pp. 883–891

Manesh R. Patel✉(Clinical Research Institute)Kenneth W. Mahaffey(Duke Medical Center)Jyotsna Garg(Duke Medical Center)Guohua Pan(Johnson & Johnson (United States))Daniel E. Singer(Massachusetts General Hospital)Werner Hacke(Heidelberg University)Günter Breithardt(University Hospital Münster)Jonathan L. Halperin(Mount Sinai Medical Center)Graeme J. Hankey(Royal Perth Hospital)Jonathan P. Piccini(Clinical Research Institute)Richard C. Becker(Clinical Research Institute)Christopher C. Nessel(Johnson & Johnson (United States))John F. Paolini(Bayer (United States))Scott D. Berkowitz(Bayer (United States))Keith A.A. Fox(University of Edinburgh)Robert M. Califf(Duke Medical Center)

View via DOI Full-text PDF

Abstract

In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism. There was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivaroxaban group. (Funded by Johnson & Johnson and Bayer; ROCKET AF ClinicalTrials.gov number, NCT00403767.).

Atrial Fibrillation Management and Outcomes Venous Thromboembolism Diagnosis and Management Cardiac Arrhythmias and TreatmentsRivaroxabanMedicineWarfarinAtrial fibrillationHazard ratioStroke (engine)Clinical endpointInternal medicineConfidence intervalEmbolism

MeSH terms

RivaroxabanAdministration, OralAgedAged, 80 and overAnticoagulantsAtrial FibrillationDouble-Blind MethodEmbolismFemaleHemorrhageHumansMaleMiddle AgedMorpholinesThiophenes

Citations

9,320

FWCI

436.33

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Stroke Risk Factors, Genetics, and Prevention